FDAsafety guidance66% confidence
FDA AP — ZOLEDRONIC ACID (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Mylan Labs; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA205254. Sponsor: MYLAN LABS LTD. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ZOLEDRONIC ACID.
Supporting Context
- Therapeutic area
- Oncology · Bone Health
- Sub-indication
- General
Related signal: FDA Accepts Supplement Application for Zoledronic Acid by Mylan Labs